Showing results (121-130 of 151) with videos related to
Sort By:
Pageof 16
The Journal of Clinical Investigation|August 1, 1993
V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials NetworkD C Montefiori, B S Graham, J Zhou, et al.Journal of Medical Primatology|September 4, 1999
Neutralizing antibody responses in Africa green monkeys naturally infected with simian immunodeficiency virus (SIVagm)M M Gicheru, M Otsyula, P Spearman, et al.Journal of Immunology (Baltimore, Md. : 1950)|April 1, 1997
Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccinesS H Pincus, K G Messer, R Cole, et al.The Journal of Infectious Diseases|December 1, 1993
Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group NetworkR B Belshe, M L Clements, R Dolin, et al.JAMA|August 10, 1994
Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials NetworkR B Belshe, B S Graham, M C Keefer, et al.The Journal of Infectious Diseases|August 11, 1992
Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials NetworkB S Graham, R B Belshe, M L Clements, et al.Journal of Clinical Microbiology|August 1, 1986
Serum immunoglobulin G antibody subclass responses to respiratory syncytial virus F and G glycoproteins after primary infectionD K Wagner, B S Graham, P F Wright, et al.Annals of Internal Medicine|August 15, 1996
Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation GroupB S Graham, M C Keefer, M J McElrath, et al.Annals of Internal Medicine|January 15, 1991
The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials NetworkR Dolin, B S Graham, S B Greenberg, et al.AIDS Research and Human Retroviruses|December 1, 1994
Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials NetworkM C Keefer, B S Graham, R B Belshe, et al.Pageof 16